- Home
- NHIV vs VCRE Comparison
NHIV vs VCRE Comparison
Compare NHIV & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NHIV | VCRE |
|---|---|---|
| Founded | 2025 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.5M | 271.7M |
| IPO Year | 2026 | 2026 |
Fundamental Metrics
Financial Performance| Metric | NHIV | VCRE |
|---|---|---|
| Price | $10.05 | $8.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 39.3K | 22.9K |
| Earning Date | N/A | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $119.57 |
| Revenue Next Year | N/A | $508.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.96 | $7.88 |
| 52 Week High | $10.16 | $13.15 |
Technical Indicators
Market Signals| Indicator | NHIV | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 46.49 | 38.01 |
| Support Level | N/A | N/A |
| Resistance Level | $10.16 | $12.63 |
| Average True Range (ATR) | 0.00 | 0.89 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 0.00 | 21.12 |
Price Performance
Historical ComparisonAbout NHIV NewHold Investment Corp IV Class A Ordinary Shares
NewHold Investment Corp IV is a blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.